Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02531919 · ClinicalTrials.gov registry record · Phase 1
Extended Use of Sodium Bicarbonate in Patients With Cancer
A Phase 1 study of Malignant Neoplasm, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT02531919: Completed Phase 1 study of Malignant Neoplasm, sponsored by University of Arizona.
NCT02531919 is a Phase 1 study of Malignant Neoplasm that has completed, run by University of Arizona. The registered enrollment target is 15 participants, below the 513-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02531919, a Phase 1 study of Malignant Neoplasm, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot phase I trial studies the safety of long-term use of sodium bicarbonate in patients with cancer. Sodium bicarbonate may neutralize tumor acidity and as a result may inhibit the spread of the tumor to other parts of the body (metastases) and improve survival.
Conditions Studied
Interventions
- DRUG Sodium Bicarbonate
Study Locations (1)
Arizona
- University of Arizona Medical Center-University Campus - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
What the finished NCT02531919 record still lists
NCT02531919 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 513-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Sodium Bicarbonate is the first listed.
NCT02531919 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT02531919 about?
NCT02531919 is a clinical study titled "Extended Use of Sodium Bicarbonate in Patients With Cancer". This pilot phase I trial studies the safety of long-term use of sodium bicarbonate in patients with cancer. Sodium bicarbonate may neutralize tumor acidity and as a result may inhibit the spread of the tumor to other parts of the body (metastases) and improve survival.
What is the current status of trial NCT02531919?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2013-08. Estimated completion is 2015-05.
What conditions does trial NCT02531919 study?
This clinical trial studies the following conditions: Malignant Neoplasm.
What interventions are being tested in trial NCT02531919?
The interventions under investigation include: Sodium Bicarbonate (DRUG).
Who is sponsoring clinical trial NCT02531919?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02531919 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02531919's enrollment target sits among peer trials
15 54th of 59 higher than 6 of 59 other Malignant Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
-
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
RECRUITING · Phase 1
-
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
RECRUITING · Phase 1
-
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia